Our audit committee reviews our internal accounting procedures, consults with and reviews the services provided by our independent registered public accountants and assists our board of directors in its oversight of our corporate accounting and financial reporting in accordance.
Ms. Giraut is currently the Chief Financial Officer of bioMérieux, a worldwide leader in in-vitro diagnostics. She previously served notably as the Chief Financial Officer of Ipsen after holding various finance leadership positions in other worldwide organizations. She also serves since 2010 as a Director of Julius Baer Group Ltd. and Bank Julius Baer & Co. Ltd., the leading Swiss private banking group. She holds a Masters from the Institut National Agronomique (AgroParisTech) in Paris.
Dr. Torbjörn Bjerke
Provides further insight and expertise into the field of allergy treatment from his extensive allergy experience as CEO of Biolipox, a Swedish pharmaceutical company that develops new treatments for inflammatory diseases. Prior to this role, Dr. Bjerke was Executive Vice President of R&D at ALK-Abello and has previously held Director of Research positions at AstraZeneca.
George Horner III
Is a pharmaceutical/biopharmaceutical executive with over 40 years of experience in the industry. Currently, Mr. Horner is a biotech executive consultant for several private companies in the United States and Europe. Previous, he was CEO of Prestwick Pharmaceuticals, a CNS company that he directed to obtain FDA approval for Tetrabenazine (TBZ), the first drug ever licensed in the United States to treat Huntington’s Disease patients. Prior to that, Mr. Horner was CEO of Vicuron Pharmaceuticals, an anti-infective company that he grew from a market value of $12.8 million to a company sold to Pfizer for $1.9 billion. Additionally, he has held numerous executive, general management, business development and marketing/sales positions with Abbott Laboratories and E.R. Squibb across 4 continents, worldwide. Mr. Horner is Chairman of the Board of Creabilis Therapeutics of Luxembourg, Chairman of the Board of Omthera Pharmaceuticals of Bedminster, New Jersey, USA, and member of the Durata Therapeutics board of directors.